Literature DB >> 2006155

Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

T K Hart1, R Kirsh, H Ellens, R W Sweet, D M Lambert, S R Petteway, J Leary, P J Bugelski.   

Abstract

Human immunodeficiency virus (HIV) infects cells after binding of the viral envelope glycoprotein gp120 to the cell surface recognition marker CD4. gp120 is noncovalently associated with the HIV transmembrane envelope glycoprotein gp41, and this complex is believed responsible for the initial stages of HIV infection and cytopathic events in infected cells. Soluble constructs of CD4 that contain the gp120 binding site inhibit HIV infection in vitro. This is believed to occur by competitive inhibition of viral binding to cellular CD4. Here we suggest an alternative mechanism of viral inhibition by soluble CD4 proteins. We demonstrate biochemically and morphologically that following binding, the soluble CD4 proteins sT4, V1V2,DT, and V1[106] (amino acids 1-369, 1-183, and -2 to 106 of mature CD4) induced the release of gp120 from HIV-1 and HIV-1-infected cells. gp120 release was concentration-, time-, and temperature-dependent. The reaction was biphasic at 37 degrees C and did not take place at 4 degrees C, indicating that binding of soluble CD4 was not sufficient to release gp120. The appearance of free gp120 in the medium after incubation with sT4 correlated with a decrease in envelope glycoprotein spikes on virions and exposure of a previously cryptic epitope near the amino terminus of gp41 on virions and infected cells. The concentration of soluble CD4 proteins needed to induce the release of gp120 from virally infected cells also correlated with those required to inhibit HIV-mediated syncytium formation. These results suggest that soluble CD4 constructs may inactivate HIV by inducing the release of gp120. We propose that HIV envelope-mediated fusion is initiated following rearrangement and/or dissociation of gp120 from the gp120-gp41 complex upon binding to cellular CD4, thus exposing the fusion domain of gp41.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006155      PMCID: PMC51195          DOI: 10.1073/pnas.88.6.2189

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site.

Authors:  D Camerini; B Seed
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

2.  Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.

Authors:  C E Fricks; J M Hogle
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Identification of the residues in human CD4 critical for the binding of HIV.

Authors:  J Arthos; K C Deen; M A Chaikin; J A Fornwald; G Sathe; Q J Sattentau; P R Clapham; R A Weiss; J S McDougal; C Pietropaolo
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

4.  CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.

Authors:  P L Nara; K M Hwang; D M Rausch; J D Lifson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  CD4-independent infection of human neural cells by human immunodeficiency virus type 1.

Authors:  J M Harouse; C Kunsch; H T Hartle; M A Laughlin; J A Hoxie; B Wigdahl; F Gonzalez-Scarano
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells.

Authors:  M Tateno; F Gonzalez-Scarano; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  Improved antigenicity of the HIV env protein by cleavage site removal.

Authors:  M P Kieny; R Lathe; Y Rivière; K Dott; D Schmitt; M Girard; L Montagnier; J Lecocq
Journal:  Protein Eng       Date:  1988-09

8.  HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens.

Authors:  D L Mann; E Read-Connole; L O Arthur; W G Robey; P Wernet; E M Schneider; W A Blattner; M Popovic
Journal:  J Immunol       Date:  1988-08-15       Impact factor: 5.422

9.  The MHC-binding and gp120-binding functions of CD4 are separable.

Authors:  D Lamarre; A Ashkenazi; S Fleury; D H Smith; R P Sekaly; D J Capon
Journal:  Science       Date:  1989-08-18       Impact factor: 47.728

10.  Enhancement of SIV infection with soluble receptor molecules.

Authors:  J S Allan; J Strauss; D W Buck
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

View more
  109 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

Authors:  R Damico; L Rong; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

4.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

6.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120.

Authors:  R L Willey; M A Martin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1.

Authors:  J P Moore
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.